Estradiol valerate/dienogest

Drug Profile

Estradiol valerate/dienogest

Alternative Names: Climodien; Climodiène; Dienogest/estradiol valerate; DNG/E2V; E2V/DNG; Klimodien; Lafamme

Latest Information Update: 02 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jenapharm
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Estradiol congeners; Estrenes; Hormonal replacements
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis
  • Preregistration Acne
  • Discontinued Pregnancy

Most Recent Events

  • 27 Jan 2017 The Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for estradiol valerate/dienogest for Acne (treatment-resistant) in European Union
  • 31 Dec 2016 Preregistration for Acne (Treatment-resistant) in European Union (PO)
  • 05 Feb 2015 Launched for Menopausal syndrome in France, Belgium, Greece, Portugal, the Czech Republic, Spain, Russia and Turkey (PO) before February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top